The trajectory of Viagra, formerly marketed by copyright, presents a intricate case study for stakeholders considering the pharmaceutical arena . Despite its early success and impact of billions in sales, the intellectual property lapse has opened the door for alternative medications, greatly diminishing earnings prospects . This transition raises